[{"data":1,"prerenderedAt":211},["ShallowReactive",2],{"drug-diazoxide":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":35,"contraindications":79,"warnings":89,"renal":96,"monitoring":97,"interactions":98,"review":99,"examples":102,"atc":117,"iran":119,"links":161,"populations":180,"usApproval":206},"diazoxide",1,{"fa":7,"en":8},"دیازوکساید","Diazoxide","various",{"fa":11,"en":12},"مهارکننده ترشح انسولین","Insulin-secretion inhibitor",[14],{"name":15,"market":16},"Proglycem","US",[18,19,20],"proglycem","پروگلایسم","دیازوکسید",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":30,"refs":31},"susp-50","suspension","oral","50 mg\u002FmL oral suspension",{"amount":28,"unit":29,"perVolumeMl":5},50,"mg",[16],[32],{"source":33,"section":34},"fda-proglycem","How Supplied",[36,59],{"id":37,"disease":38,"label":39,"population":42,"type":45,"unit":29,"dose":46,"refs":49,"notes":52},"std","hypoglycemia",{"fa":40,"en":41},"هیپوگلیسمی ناشی از هیپرانسولینیسم (بزرگسال و کودک) — شروع ۳ mg\u002Fkg\u002Fروز در ۳ دوز هر ۸ ساعت؛ حداکثر ۸","Hyperinsulinaemic hypoglycaemia (adults and children) — start 3 mg\u002Fkg\u002Fday in 3 doses every 8 h; max 8",{"minAge":43},{"value":5,"unit":44},"year","weightBased",{"perKgPerDay":47,"perKgPerDayMax":48,"dividedDoses":47},3,8,[50],{"source":33,"section":51},"Dosage and Administration",[53],{"text":54,"refs":57},{"fa":55,"en":56},"یا در ۲ دوز هر ۱۲ ساعت. اگر پس از ۲ تا ۳ هفته مؤثر نبود قطع شود.","Or in 2 doses every 12 h. Stop if ineffective after 2–3 weeks.",[58],{"source":33,"section":51},{"id":60,"disease":38,"label":61,"population":64,"type":45,"unit":29,"dose":66,"refs":68,"notes":70},"infant",{"fa":62,"en":63},"شیرخوار و نوزاد — شروع ۸ mg\u002Fkg\u002Fروز در ۳ دوز هر ۸ ساعت؛ حداکثر ۱۵","Infants and newborns — start 8 mg\u002Fkg\u002Fday in 3 doses every 8 h; max 15",{"maxAge":65},{"value":5,"unit":44},{"perKgPerDay":48,"perKgPerDayMax":67,"dividedDoses":47},15,[69],{"source":33,"section":51},[71],{"text":72,"refs":75},{"fa":73,"en":74},"دقت دوز در شیرخوار بسیار مهم است. فشار ریوی (PH) در نوزاد گزارش شده.","Dose accuracy is critical in infants. Pulmonary hypertension has been reported in newborns.",[76,77],{"source":33,"section":51},{"source":33,"section":78},"Warnings",[80],{"id":81,"severity":82,"text":83,"refs":86},"ci","block",{"fa":84,"en":85},"هیپوگلیسمی عملکردی؛ حساسیت به دیازوکساید یا تیازیدها.","Functional hypoglycaemia; hypersensitivity to diazoxide or other thiazides.",[87],{"source":33,"section":88},"Contraindications",[90],{"text":91,"refs":94},{"fa":92,"en":93},"احتباس مایع و نارسایی قلب؛ کتواسیدوز و کمای هیپراسمولار؛ با تیازید افزایش قند و اسید اوریک.","Fluid retention and heart failure; ketoacidosis and hyperosmolar coma; thiazides potentiate hyperglycaemia and hyperuricaemia.",[95],{"source":33,"section":78},[],[],[],{"status":100,"reviewer":101,"date":101},"unverified",null,[103,110],{"regimen":37,"formulation":23,"input":104,"expect":107},{"ageYears":105,"weightKg":106},6,20,{"perDose":106,"mlPerDose":108,"upperPerDose":109},0.4,53.33,{"regimen":60,"formulation":23,"input":111,"expect":113},{"ageMonths":112,"weightKg":105},4,{"perDose":114,"mlPerDose":115,"upperPerDose":116},16,0.32,30,[118],"V03AH01",{"status":120,"forms":121,"refs":156},"registered",[122,126,130,134,138,142,146,150,153],{"code":123,"en":124,"fa":125},"00421","DIAZOXIDE 100MG CAP","کپسول دیازوکساید ۱۰۰ میلی‌گرم",{"code":127,"en":128,"fa":129},"05813","DIAZOXIDE 100MG TAB","قرص دیازوکساید ۱۰۰ میلی‌گرم",{"code":131,"en":132,"fa":133},"01959","DIAZOXIDE 25MG CAP","کپسول دیازوکساید ۲۵ میلی‌گرم",{"code":135,"en":136,"fa":137},"05812","DIAZOXIDE 25MG TAB","قرص دیازوکساید ۲۵ میلی‌گرم",{"code":139,"en":140,"fa":141},"01463","DIAZOXIDE 50MG CAP","کپسول دیازوکساید ۵۰ میلی‌گرم",{"code":143,"en":144,"fa":145},"13938","DIAZOXIDE 50MG TAB","قرص دیازوکساید ۵۰ میلی‌گرم",{"code":147,"en":148,"fa":149},"00423","DIAZOXIDE 50MG\u002F5ML 30ML SYR","دیازوکساید ۵۰ میلی‌گرم \u002F ۵ میلی‌لیتر ۳۰ میلی‌لیتر",{"code":151,"en":152,"fa":145},"52351","DIAZOXIDE TABLET ORAL 50 mg",{"code":154,"en":155,"fa":133},"52481","DIAZOXIDE CAPSULE ORAL 25 mg",[157],{"source":158,"section":159,"url":160},"darooyab-generic","G-1632\u002FDiazoxide-Oral","https:\u002F\u002Fwww.darooyab.ir\u002FG-1632\u002FDiazoxide-Oral",[162,166,170,174,177],{"kind":163,"url":164,"label":165},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=017453","NDA017453",{"kind":167,"url":168,"label":169},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=b16c7832-2fd9-49af-b923-1dc0d91fd6e2","FDA Proglycem",{"kind":171,"url":172,"label":173},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa625073.html","Diazoxide Choline",{"kind":175,"url":176,"label":118},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=V03AH01",{"kind":178,"url":160,"label":179},"darooyab","Diazoxide-Oral",{"lactation":181,"pediatric":190,"pregnancy":198},{"level":182,"text":183,"quote":186,"refs":187},"caution",{"fa":184,"en":185},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Information is not available concerning the passage of diazoxide in breast milk.",[188],{"source":33,"section":189},"Nursing Mothers",{"level":182,"text":191,"quote":194,"refs":195},{"fa":192,"en":193},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","See INDICATIONS AND USAGE .",[196],{"source":33,"section":197},"Pediatric Use",{"level":182,"quote":199,"text":200,"refs":203},"مصرف در بارداری دیازوکساید خوراکی گروه C در شرايط خاص و نظارت ويژه پزشك قابل استفاده است:",{"fa":201,"en":202},"دارویاب: گروه C — فقط اگر فایده بیشتر از خطر باشد.","Darooyab: category C — only if benefit outweighs risk.",[204],{"source":158,"section":205,"url":160},"G-1632\u002FDiazoxide-Oral — مصرف در بارداری",{"kind":207,"refs":208,"id":165},"NDA",[209],{"source":33,"section":210},"SPL approval \u002F marketing category",1792191537673]